Autolus Therapeutics (AUTL) to Release Quarterly Earnings on Tuesday

Autolus Therapeutics (NASDAQ:AUTL) is scheduled to be announcing its earnings results before the market opens on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.21) per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.03). On average, analysts expect Autolus Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Autolus Therapeutics Trading Down 7.7 %

Shares of AUTL stock opened at $3.73 on Monday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.55 and a current ratio of 18.55. The stock has a fifty day simple moving average of $3.99 and a two-hundred day simple moving average of $4.01. The firm has a market capitalization of $992.53 million, a PE ratio of -3.22 and a beta of 2.04. Autolus Therapeutics has a 52-week low of $3.06 and a 52-week high of $7.45.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.